APA (7th ed.) Citation

E, R., G, B., R, C., K, S., JLD, B., C, D., . . . MJ, S. (2026). Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study. Urologic oncology, 44(4), 111028. https://doi.org/10.1016/j.urolonc.2026.111028

Chicago Style (17th ed.) Citation

E, Rinderknecht, et al. "Progression-free Survival with Darolutamide and Docetaxel Vs. Androgen Receptor Pathway Inhibitors Vs. Docetaxel in Metastatic Hormone-sensitive Prostate Cancer: A Real-world Multicenter Retrospective Study." Urologic Oncology 44, no. 4 (2026): 111028. https://doi.org/10.1016/j.urolonc.2026.111028.

MLA (9th ed.) Citation

E, Rinderknecht, et al. "Progression-free Survival with Darolutamide and Docetaxel Vs. Androgen Receptor Pathway Inhibitors Vs. Docetaxel in Metastatic Hormone-sensitive Prostate Cancer: A Real-world Multicenter Retrospective Study." Urologic Oncology, vol. 44, no. 4, 2026, p. 111028, https://doi.org/10.1016/j.urolonc.2026.111028.